Advertisement
News
Advertisement

NeoStem Adds Distinguished Researcher to its World-Class Scientific Advisory Board

Thu, 07/01/2010 - 8:34am
Bio-Medicine.Org

NEW YORK, July 1 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, today announced that it has appointed Roberto Bolli, M.D., to its Scientific Advisory Board. Dr. Bolli has produced an immense body of stem-cell research, including work emphasizing the ability of very small embryonic-like stem cells (VSELs) to regenerate and repair after myocardial infarction. He has received numerous awards and honors, produced over 300 peer-reviewed publications and lectured various audiences on topics related to his cardiovascular research, which has spanned three decades.

Dr. Bolli currently serves as Chief of the Division of Cardiology at the University of Louisville and is Director at the school's Institute of Molecular Cardiology. He also has been named Executive Vice Chairman of University of Louisville's Department of Medicine. He holds the Jewish Hospital Distinguished Chair in Cardiology and has pioneered, developed and led research programs from the ground up at both Baylor University and the University of Louisville.

Wayne A. Marasco, M.D., Ph.D., chair of NeoStem's Scientific Advisory Board, said, "We are extremely pleased to have Dr. Bolli join our advisory team. His in-depth understanding of the intricacies of VSELs and their potential to regenerate damaged heart tissue compliments well our goal of commercializing VSEL(TM) technology to improve the

'/>"/>

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading